Authors: Ekholm, E Rantanen, V Bergman, M Vesalainen, R Antila, K Salminen, E

Citation: E. Ekholm et al., Docetaxel and autonomic cardiovascular control in anthracycline treated breast cancer patients, ANTICANC R, 20(3B), 2000, pp. 2045-2048

Authors: Jarvinen, TAH Tanner, M Rantanen, V Barlund, M Borg, A Grenman, S Isola, J

Citation: Tah. Jarvinen et al., Amplification and deletion of topoisomerase II alpha associate with ErbB-2amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer, AM J PATH, 156(3), 2000, pp. 839-847

Authors: Engblom, P Pulkkinen, JO Rantanen, V Hirvonen, H Kulmala, J Grenman, R Grenman, S

Citation: P. Engblom et al., Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis, EUR J CANC, 35(2), 1999, pp. 284-288

Authors: Engblom, P Rantanen, V Kulmala, J Grenman, S

Citation: P. Engblom et al., Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effectin epithelial ovarian carcinoma in vitro, CANCER, 86(10), 1999, pp. 2066-2073

Authors: Engblom, P Rantanen, V Kulmala, J Helenius, H Grenman, S

Citation: P. Engblom et al., Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines, BR J CANC, 79(2), 1999, pp. 286-292

Authors: Rantanen, V Grenman, S Kurvinen, K Hietanen, S Raitanen, M Syrjanen, S

Citation: V. Rantanen et al., p53 mutations and presence of HPV DNA do not correlate with radiosensitivity of gynecological cancer cell lines, GYNECOL ONC, 71(3), 1998, pp. 352-358